A Model‐Based Meta‐Analysis of Pembrolizumab Effects on Patient‐Reported Quality of Life: Advancing Patient‐Centered Oncology Drug Development
CPT: Pharmacometrics & Systems Pharmacology · 2026
DOI: 10.1002/psp4.70106 ↗Kurz gefasst
Metaanalyse in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, 2026. Verfasst von Yiqin Zou und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina, US…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Quality of Life, Patient Reported Outcome Measures, Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Pembrolizumab is an immune checkpoint inhibitor that has been approved for more than 20 different indications and has shown great survival benefits in various types of cancer. However, the reported benefits of pembrolizumab in patients' quality of life (QoL) have been inconsistent across different studies and different types of cancer. As oncology drug development increasingly emphasizes patient‐centered care, patient‐reported outcomes (PROs), particularly patient‐reported QoL, are recognized as important clinical endpoints. To characterize the effects of pembrolizumab on patient‐reported QoL, we conducted a model‐based meta‐analysis (MBMA) of published clinical trials evaluating pembrolizumab across different types of cancer. The longitudinal EORTC QLQ‐C30 GHS/QOL data were extracted in our analysis as QoL scores. A population model was developed to characterize the longitudinal QoL trajectories and quantify both treatment toxicity and efficacy. Out of more than 300 screened studies, only 20 reported longitudinal EORTC QLQ‐C30 QoL data. Among these, 8 studies reported no between‐group differences in QoL outcomes between pembrolizumab and control arms. However, our modeling revealed that pembrolizumab was associated with greater toxicity but improved long‐term QoL. Notably, our approach identified treatment effects on QoL that were not detected by traditional statistical analyses in the original publications. In summary, our study demonstrates that MBMA combined with population modeling enables more accurate evaluation of longitudinal PROs data, overcoming the limitations of conventional methods. This approach offers a robust framework for integrating patient‐centered outcomes into oncology drug development and supports the broader use of PROs data in regulatory and clinical decision‐making.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina, USA.
- Princeton International School of Mathematics and Science, Princeton, New Jersey, USA.
- Gillings School of Global Public Health, University of North Carolina, Chapel Hill, North Carolina, USA.
- Lineberger Comprehensive Cancer Center, School of Medicine, University of North Carolina, Chapel Hill, North Carolina, USA.
ORCID-Profile: Lynne I Wagner, Jiawei Zhou
Zitieren
APA
Zou, Y., Sun, Y., Ravva, S., Wagner, L. I., & Zhou, J. (2026). A Model‐Based Meta‐Analysis of Pembrolizumab Effects on Patient‐Reported Quality of Life: Advancing Patient‐Centered Oncology Drug Development. CPT: Pharmacometrics & Systems Pharmacology. https://doi.org/10.1002/psp4.70106
Vancouver
Zou Y, Sun Y, Ravva S, Wagner LI, Zhou J. A Model‐Based Meta‐Analysis of Pembrolizumab Effects on Patient‐Reported Quality of Life: Advancing Patient‐Centered Oncology Drug Development. CPT: Pharmacometrics & Systems Pharmacology. 2026. doi:10.1002/psp4.70106
BibTeX
@article{Zou2026,
author = {Zou, Yiqin and Sun, Yimeng and Ravva, Sudhamshu and Wagner, Lynne I and Zhou, Jiawei},
title = {A Model‐Based Meta‐Analysis of Pembrolizumab Effects on Patient‐Reported Quality of Life: Advancing Patient‐Centered Oncology Drug Development},
journal = {CPT: Pharmacometrics & Systems Pharmacology},
year = {2026},
doi = {10.1002/psp4.70106}
}
EUVIMED